Daily news and updates provided by the NEUROSURGERY® Editorial Office

Posts Tagged ‘glioblastoma

Ahead of Print: Regression of Recurrent Malignant Gliomas with Convection-Enhanced Delivery of Topotecan

Full article access for Neurosurgery subscribers at

BACKGROUND: Convection-enhanced delivery of chemotherapeutics for the treatment of malignant glioma is a technique that delivers drugs directly into a tumor and the surrounding interstitium through chronic, low grade positive-pressure infusion. This allows for high local concentrations of drug while overcoming the limitations imposed by toxicity and the blood-brain barrier in systemic therapies that prevent the use of many potentially effective drugs.

OBJECTIVE: To examine the safety profile of a conventional chemotherapeutic agent, topotecan, via convection-enhanced delivery in the treatment of recurrent malignant gliomas and, secondarily, to assess radiographic response and survival.

METHODS: We performed a prospective, dose-escalation Phase Ib study of the topoisomerase-I inhibitor, topotecan, given by convection-enhanced delivery in patients with recurrent malignant gliomas.

Read the rest of this entry »

Written by NEUROSURGERY® Editorial Office

June 20, 2011 at 9:00 AM

Ahead of Print: 14-3-3zeta positive expression is associated with a poor prognosis in patients with glioblastoma

Full article access for Neurosurgery subscribers.

BACKGROUND: When identifying clinical markers predicting clinical outcome, disease recurrence and resistance to therapies often determine the diagnosis and therapy of some cancer types.

OBJECTIVE: To investigate whether 14-3-3zeta positive expression is an indicator of prognosis in patients with glioblastoma.

METHODS: Forty-seven patients treated with surgery, radiotherapy, and adjuvant chemotherapy between 2005 and 2007 were divided into two groups according to 14-3-3zeta expression in an immunohistochemical study: the 14-3-3zeta negative group (n = 12 patients) and the 14-3-3zeta positive group (n = 35 patients). The clinicopathologic features and survival data for patients in the 14-3-3zeta positive group were compared with data from the patients in the 14-3-3zeta negative group. Kaplan-Meier survival analysis and univariate and multivariate analysis were performed to determine the prognostic factors that influenced patient survival.

Read the rest of this entry »

Written by NEUROSURGERY® Editorial Office

January 18, 2011 at 10:16 AM

Ahead of Print: Magnetic Resonance Imaging Characteristics of Glioblastoma Multiforme: Implications for Understanding Glioma Ontogeny

Full article access for Neurosurgery subscribers.

Bohman, Leif-Erik MD; Swanson, Kristin R PhD; Moore, Julia L BS; Rockne, Russ MS; Mandigo, Christopher MD; Hankinson, Todd MD, MBA; Assanah, Marcela PhD; Canoll, Peter MD, PhD; Bruce, Jeffrey N MD

BACKGROUND: Identifying the origin of gliomas carries important implications for advancing the treatment of these recalcitrant tumors. Recent research promotes the hypothesis of a subventricular zone (SVZ) origin for the stemlike gliomagenic cells identified within human glioma specimens. However, conflicting evidence suggests that SVZ-like cells are not uniquely gliomagenic but this capacity may be shared by cycling progenitors distributed throughout the subcortical white matter (SCWM).

OBJECTIVE: To review radiological evidence in glioblastoma multiforme (GBM) patients to provide insight into the question of glioma ontogeny.

METHODS: We explored whether GBMs at first diagnosis demonstrated a pattern of anatomic distribution consistent with origin at the SVZ through retrospective analysis of preoperative contrast-enhanced T1-weighted magnetic resonance images in 63 patients. We then examined the relationship of tumor volume, point of origin, and proximity to the ventricles using a computer model of glioma growth.

Read the rest of this entry »

Written by NEUROSURGERY® Editorial Office

September 28, 2010 at 9:10 AM

Free Article: Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007

Free full text access.

Scoccianti, Silvia MD; Magrini, Stefano Maria MD; Ricardi, Umberto MD; Detti, Beatrice MD; Buglione, Michela MD; Sotti, Guido MD; Krengli, Marco MD; Maluta, Sergio MD; Parisi, Salvatore MD; Bertoni, Filippo MD; Mantovani, Cristina MD; Tombolini, Vincenzo MD; De Renzis, Costantino MD; Lioce, Marco MD; Fatigante, Lucia MD; Fusco, Vincenzo MD; Muto, Paolo MD; Berti, Franco MD; Rubino, Giovanni MD; Cipressi, Samantha MD; Fariselli, Laura MD; Lupattelli, Marco MD; Santoni, Riccardo MD; Pirtoli, Luigi MD; Biti, Giampaolo MD

OBJECTIVE: To investigate the pattern of care and outcomes for newly diagnosed glioblastoma in Italy and compare our results with the previous Italian Patterns of Care study to determine whether significant changes occurred in clinical practice during the past 10 years.

METHODS: Clinical, pathological, therapeutic, and survival data regarding 1059 patients treated in 18 radiotherapy centers between 2002 and 2007 were collected and retrospectively reviewed. Read the rest of this entry »

Written by NEUROSURGERY® Editorial Office

July 29, 2010 at 9:35 AM

Cancer Stem Cells Suppress Immune Response Against Brain Tumor

ScienceDaily (2010-01-15) Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists have found.


Written by NEUROSURGERY® Editorial Office

January 16, 2010 at 9:47 PM

Posted in News

Tagged with , ,


Get every new post delivered to your Inbox.

Join 13,744 other followers